IKZF1 deletions in pediatric acute lymphoblastic leukemia: Still a poor prognostic marker?

International BFM Study Group

Research output: Contribution to journalArticlepeer-review

Abstract

Improved personalized adjustment of primary therapy to the perceived risk of relapse by using new prognostic markers for treatment stratification may be beneficial to patients with acute lymphoblastic leukemia (ALL). Here, we review the advances that have shed light on the role of IKZF1 aberration as prognostic factor in pediatric ALL and summarize emerging concepts in this field. Continued research on the interplay of disease biology with exposure and response to treatment will be key to further improve treatment strategies.

Original languageEnglish (US)
Pages (from-to)252-260
Number of pages9
JournalBlood
Volume135
Issue number4
DOIs
StatePublished - Jan 23 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'IKZF1 deletions in pediatric acute lymphoblastic leukemia: Still a poor prognostic marker?'. Together they form a unique fingerprint.

Cite this